Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares (2020 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 5 years of Preferred Shares data on record, last reported at $127.7 million in Q3 2025.

  • For Q3 2025, Preferred Shares changed 0.0% year-over-year to $127.7 million; the TTM value through Sep 2025 reached $127.7 million, changed 0.0%, while the annual FY2024 figure was $127.7 million, 63.22% up from the prior year.
  • Preferred Shares reached $127.7 million in Q3 2025 per VRDN's latest filing, up from $61.2 million in the prior quarter.
  • Across five years, Preferred Shares topped out at $145.8 million in Q3 2021 and bottomed at $15.7 million in Q4 2021.
  • Average Preferred Shares over 5 years is $85.2 million, with a median of $78.2 million recorded in 2023.
  • Peak YoY movement for Preferred Shares: skyrocketed 261.71% in 2022, then plummeted 52.3% in 2025.
  • A 5-year view of Preferred Shares shows it stood at $15.7 million in 2021, then surged by 261.71% to $56.7 million in 2022, then skyrocketed by 38.04% to $78.2 million in 2023, then soared by 63.22% to $127.7 million in 2024, then changed by 0.0% to $127.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Preferred Shares were $127.7 million in Q3 2025, $61.2 million in Q2 2025, and $127.7 million in Q1 2025.